$LCUT

LIFETIME BRANDS, INC (LCUT): Results of Operations and Financial Condition

LIFETIME BRANDS, INC (LCUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99108062026.htm EX-99.1 Document Exhibit 99.1 Lifetime Brands, Inc. Reports Second Quarter 2026 Financial Results Declares Regular Quarterly Dividend GARDEN CITY, NY, August 6, 2026 – Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and mar

Original reporting
Published Aug 6, 2026, 12:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LCUT
Bullish
medium confidence
Mentioned
$LCUT
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LCUTBullishMed
01

Why it matters

The filing quantifies tariff refund benefits ($40.1M in Q2) that boosted gross margin and operating income, and it states earnings guidance was raised while net sales guidance was reaffirmed. It also notes $40M term debt repaid since Q1 using operating cash and tariff refunds.

02

Market read

Traders can update expectations for 2026 earnings quality and balance-sheet trajectory based on the quantified tariff refund benefit and the stated guidance adjustment.

03

What to watch

Startup challenges at the new Hagerstown facility and ongoing softer end markets could offset margin gains later in 2026, even with guidance raised.

Relevance 7/10Novelty 7/10Timing: filed pre-market today (Aug 6, 2026) with Q2 results and guidance update

Background

This is an SEC Form 8-K (Item 2.02) reporting Lifetime Brands’ Q2 2026 results and financial condition, including commentary on tariff impacts and refunds.

Company-level read

Ticker impact

$LCUTBullishMedium confidence
Context

Lifetime Brands reported Q2 net sales up 7.4% and said gross margin benefited from a $40.1M tariff refund, lifting operating income versus last year.

Expected impact

Near-term upside bias if investors believe tariff refunds are repeatable and the balance-sheet repair (debt repayment) continues.

Evidence & confidence

The filing provides concrete P&L impacts from tariff refunds ($40.1M) and states earnings guidance is raised, which can re-rate expectations, but durability of refunds is not quantified.

Market effects

Highlights how tariff policy and refund mechanics can materially affect consumer-brands margins and earnings quality.

Limited direct regional read-through; impacts are tied to international tariff exposure and refunds.

Signals tariff-related cost normalization dynamics that can influence other import-exposed consumer goods firms’ margin expectations.

Counterpoint

The earnings beat may be largely non-recurring tariff refund benefit, so valuation upside could fade if refunds are one-time or timing-shifted.

Key entities

  • Lifetime Brands, Inc.

    Nasdaq-listed consumer products company reporting Q2 2026 results, tariff refund benefit, and guidance changes.

  • Rob Kay

    CEO quoted on tariff recovery, debt repayment, and segment progress toward break-even in 2026.

Related articles

$LCUTMedAI 8/10

Lifetime Brands (LCUT) Q2 2026 Earnings Call Transcript

Lifetime Brands (LCUT) reported Q2 2026 net sales of $141.6 million, up 7.4%, and net income of $19.6 million, or $0.87 diluted EPS. Gross margin was 65.9% aided by a $40.1 million IEEPA tariff refund. Adjusted EPS was $1.18. FY guidance: net sales $650-$700 million and adjusted EBITDA $90.5-$93 million.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CDNSMed

CDNS Falls 12.9% in the Past Month. Is the Sell-Off an Opportunity?

Cadence Design Systems (CDNS) shares fell 12.9% over the past month despite Q2 results. According to the company, Q2 revenue rose 24.2% to $1.584B and non-GAAP EPS rose 27.9% to $2.11. The company raised 2026 guidance to $6.26-$6.34B revenue and $8.05-$8.15 EPS, with backlog at a record $8.1B. Valuation remains at 36.3x forward earnings.

$AIRTMedAI 8/10

Air T, Inc. Continues Track Record of Growth in First Quarter Fiscal 2027: Crestone Completes Acquisition of Arena

Air T, Inc. (NASDAQ:AIRT) reported fiscal 2027 first-quarter results for the period ended June 30, 2026. Revenue rose to $115.5 million, up 63% year over year, while operating loss widened to $12.8 million. Adjusted EBITDA was $0.8 million, down 45%. The company said results were pressured by acquisition and integration costs tied to Crestone’s Arena deal and non-cash depreciation from purchase accounting. Crestone acquired Arena Aviation Capital for $33.9 million.